Michael Becker to Young Adult
This is a "connection" page, showing publications Michael Becker has written about Young Adult.
Connection Strength
0.247
-
Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study). Arthritis Rheumatol. 2017 01; 69(1):203-212.
Score: 0.060
-
Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes Obes Metab. 2013 Nov; 15(11):1049-55.
Score: 0.047
-
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12(2):R63.
Score: 0.038
-
Trade-off in object versus spatial visualization abilities: restriction in the development of visual-processing resources. Psychon Bull Rev. 2010 Feb; 17(1):29-35.
Score: 0.037
-
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May; 165(4):504-9.
Score: 0.012
-
A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation. Biol Blood Marrow Transplant. 2013 Dec; 19(12):1745-52.
Score: 0.012
-
Proteomic pattern analysis discriminates among multiple sclerosis-related disorders. Ann Neurol. 2012 May; 71(5):614-23.
Score: 0.011
-
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012 Feb; 64(2):256-61.
Score: 0.011
-
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. Biol Blood Marrow Transplant. 2011 Jul; 17(7):1033-42.
Score: 0.010
-
Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009 Feb; 48(2):188-94.
Score: 0.009